Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study in Adult Subjects With Acute Migraines

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03235479
Recruitment Status : Completed
First Posted : August 1, 2017
Results First Posted : December 23, 2020
Last Update Posted : January 22, 2021
Sponsor:
Information provided by (Responsible Party):
Biohaven Pharmaceuticals, Inc.

Study Type Interventional
Study Design Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Triple (Participant, Care Provider, Investigator);   Primary Purpose: Treatment
Condition Migraine, With or Without Aura
Interventions Drug: Rimegepant
Drug: Placebo
Enrollment 1485
Recruitment Details The study was conducted at 50 centers in the United States.
Pre-assignment Details A total of 1485 participants were enrolled, of which 1162 participants were randomized to BHV-3000 (rimegepant) 75 milligram (mg) or placebo. A total of 323 participants failed screening mainly due to failure to meet eligibility criteria.The randomization was stratified in a 1:1 ratio based on use of prophylactic migraine medications (yes or no).
Arm/Group Title Rimegepant 75 mg Placebo
Hide Arm/Group Description Participants were administered a single oral dose of 75 mg of rimegepant on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization. Participants were administered a single oral dose of matching placebo for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Period Title: Overall Study
Started [1] 582 580
Treated 546 549
Completed 541 540
Not Completed 41 40
Reason Not Completed
Lost to Follow-up             8             11
Not Experienced Moderate/Severe Migraine             23             17
Pregnancy             1             0
Protocol Deviation             1             3
Technical Problems             3             2
Withdrawal by Subject             2             2
Other Reasons             3             5
[1]
Randomized
Arm/Group Title Rimegepant 75 mg Placebo Total
Hide Arm/Group Description Participants were administered a single oral dose of 75 mg of rimegepant on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization. Participants were administered a single oral dose of matching placebo for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization. Total of all reporting groups
Overall Number of Baseline Participants 543 541 1084
Hide Baseline Analysis Population Description
The analysis was performed on modified intent to treat (mITT) participants, defined as those who were randomized only once, took study medication, had moderate to severe pain level at migraine onset, and who provided at least 1 post-dose efficacy measurement (i.e., after taking study medication).
Age, Continuous  
Mean (Standard Deviation)
Unit of measure:  Years
Number Analyzed 543 participants 541 participants 1084 participants
41.945  (12.3286) 41.326  (12.1381) 41.636  (12.2322)
Sex: Female, Male  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 543 participants 541 participants 1084 participants
Female
464
  85.5%
463
  85.6%
927
  85.5%
Male
79
  14.5%
78
  14.4%
157
  14.5%
Ethnicity (NIH/OMB)  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 543 participants 541 participants 1084 participants
Hispanic or Latino
58
  10.7%
68
  12.6%
126
  11.6%
Not Hispanic or Latino
485
  89.3%
473
  87.4%
958
  88.4%
Unknown or Not Reported
0
   0.0%
0
   0.0%
0
   0.0%
Race (NIH/OMB)  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 543 participants 541 participants 1084 participants
American Indian or Alaska Native
1
   0.2%
3
   0.6%
4
   0.4%
Asian
6
   1.1%
7
   1.3%
13
   1.2%
Native Hawaiian or Other Pacific Islander
2
   0.4%
0
   0.0%
2
   0.2%
Black or African American
107
  19.7%
80
  14.8%
187
  17.3%
White
417
  76.8%
444
  82.1%
861
  79.4%
More than one race
10
   1.8%
7
   1.3%
17
   1.6%
Unknown or Not Reported
0
   0.0%
0
   0.0%
0
   0.0%
Primary Migraine Type  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 543 participants 541 participants 1084 participants
Migraine without Aura
353
  65.0%
358
  66.2%
711
  65.6%
Migraine with Aura
190
  35.0%
183
  33.8%
373
  34.4%
Randomization Strata, Prophylactic Migraine Medication Use  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 543 participants 541 participants 1084 participants
Yes
90
  16.6%
92
  17.0%
182
  16.8%
No
453
  83.4%
449
  83.0%
902
  83.2%
1.Primary Outcome
Title Percentage of Participants With Freedom From Pain at 2 Hours Post-dose
Hide Description Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the electronic diary (eDiary). Pain freedom was defined as pain level of none.
Time Frame 2 hours post-dose
Hide Outcome Measure Data
Hide Analysis Population Description
The analysis was performed on modified intent to treat (mITT) participants.
Arm/Group Title Rimegepant 75 mg Placebo
Hide Arm/Group Description:
Participants were administered a single oral dose of 75 mg of rimegepant on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Participants were administered a single oral dose of matching placebo for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Overall Number of Participants Analyzed 543 541
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants
19.2
(15.8 to 22.5)
14.2
(11.3 to 17.2)
Hide Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Rimegepant 75 mg, Placebo
Comments [Not Specified]
Type of Statistical Test Superiority
Comments [Not Specified]
Statistical Test of Hypothesis P-Value 0.0298
Comments [Not Specified]
Method Cochran-Mantel-Haenszel
Comments [Not Specified]
Method of Estimation Estimation Parameter Risk Difference (RD)
Estimated Value 4.9
Confidence Interval (2-Sided) 95%
0.5 to 9.3
Estimation Comments [Not Specified]
2.Primary Outcome
Title Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose
Hide Description MBS was reported as nausea, photophobia, or phonophobia at migraine onset using the eDiary. Symptom status (absent, present) was assessed post-dose using the eDiary separately for nausea, photophobia, and phonophobia. Freedom from MBS was defined as MBS reported at onset that was absent post-dose.
Time Frame 2 hours post-dose
Hide Outcome Measure Data
Hide Analysis Population Description
The analysis was performed on mITT participants.
Arm/Group Title Rimegepant 75 mg Placebo
Hide Arm/Group Description:
Participants were administered a single oral dose of 75 mg of rimegepant on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Participants were administered a single oral dose of matching placebo for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Overall Number of Participants Analyzed 543 541
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants
36.6
(32.6 to 40.7)
27.7
(24.0 to 31.5)
Hide Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Rimegepant 75 mg, Placebo
Comments [Not Specified]
Type of Statistical Test Superiority
Comments [Not Specified]
Statistical Test of Hypothesis P-Value 0.0016
Comments [Not Specified]
Method Cochran-Mantel-Haenszel
Comments [Not Specified]
Method of Estimation Estimation Parameter Risk Difference (RD)
Estimated Value 8.9
Confidence Interval (2-Sided) 95%
3.4 to 14.4
Estimation Comments [Not Specified]
3.Secondary Outcome
Title Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose
Hide Description Photophobia (sensitivity to light) status was measured as absent or present in the eDiary. Freedom from photophobia was defined as photophobia absent.
Time Frame 2 hours post-dose
Hide Outcome Measure Data
Hide Analysis Population Description
The analysis was performed on mITT participants with photophobia present at migraine onset.
Arm/Group Title Rimegepant 75 mg Placebo
Hide Arm/Group Description:
Participants were administered a single oral dose of 75 mg of rimegepant on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Participants were administered a single oral dose of matching placebo for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Overall Number of Participants Analyzed 470 483
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants
34.9
(30.6 to 39.2)
24.8
(20.9 to 28.6)
Hide Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Rimegepant 75 mg, Placebo
Comments [Not Specified]
Type of Statistical Test Superiority
Comments [Not Specified]
Statistical Test of Hypothesis P-Value 0.0005
Comments [Not Specified]
Method Cochran-Mantel-Haenszel
Comments [Not Specified]
Method of Estimation Estimation Parameter Risk Difference (RD)
Estimated Value 10.2
Confidence Interval (2-Sided) 95%
4.4 to 15.9
Estimation Comments [Not Specified]
4.Secondary Outcome
Title Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose
Hide Description Phonophobia (sensitivity to sound) status was measured as absent or present in the eDiary. Freedom from phonophobia was defined as phonophobia absent.
Time Frame 2 hours post-dose
Hide Outcome Measure Data
Hide Analysis Population Description
The analysis was performed on mITT participants with phonophobia present at migraine onset.
Arm/Group Title Rimegepant 75 mg Placebo
Hide Arm/Group Description:
Participants were administered a single oral dose of 75 mg of rimegepant on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Participants were administered a single oral dose of matching placebo for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Overall Number of Participants Analyzed 345 366
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants
38.6
(33.4 to 43.7)
30.9
(26.2 to 35.5)
Hide Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Rimegepant 75 mg, Placebo
Comments [Not Specified]
Type of Statistical Test Superiority
Comments [Not Specified]
Statistical Test of Hypothesis P-Value 0.0299
Comments [Not Specified]
Method Cochran-Mantel-Haenszel
Comments [Not Specified]
Method of Estimation Estimation Parameter Risk Difference (RD)
Estimated Value 7.7
Confidence Interval (2-Sided) 95%
0.8 to 14.6
Estimation Comments [Not Specified]
5.Secondary Outcome
Title Percentage of Participants With Pain Relief at 2 Hours Post-dose
Hide Description Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eDiary. Pain relief was defined as pain level of none or mild.
Time Frame 2 hours post-dose
Hide Outcome Measure Data
Hide Analysis Population Description
The analysis was performed on mITT participants.
Arm/Group Title Rimegepant 75 mg Placebo
Hide Arm/Group Description:
Participants were administered a single oral dose of 75 mg of rimegepant on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Participants were administered a single oral dose of matching placebo for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Overall Number of Participants Analyzed 543 541
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants
56.0
(51.8 to 60.2)
45.7
(41.5 to 49.9)
Hide Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Rimegepant 75 mg, Placebo
Comments [Not Specified]
Type of Statistical Test Superiority
Comments [Not Specified]
Statistical Test of Hypothesis P-Value 0.0006
Comments [Not Specified]
Method Cochran-Mantel-Haenszel
Comments [Not Specified]
Method of Estimation Estimation Parameter Risk Difference (RD)
Estimated Value 10.3
Confidence Interval (2-Sided) 95%
4.4 to 16.2
Estimation Comments [Not Specified]
6.Secondary Outcome
Title Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose
Hide Description Nausea status was measured as absent or present in the eDiary. Freedom from nausea was defined as nausea absent.
Time Frame 2 hours post-dose
Hide Outcome Measure Data
Hide Analysis Population Description
The analysis was performed on mITT participants with nausea present at migraine onset.
Arm/Group Title Rimegepant 75 mg Placebo
Hide Arm/Group Description:
Participants were administered a single oral dose of 75 mg of rimegepant on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Participants were administered a single oral dose of matching placebo for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Overall Number of Participants Analyzed 318 322
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants
46.9
(41.4 to 52.3)
41.6
(36.2 to 47.0)
Hide Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Rimegepant 75 mg, Placebo
Comments [Not Specified]
Type of Statistical Test Superiority
Comments [Not Specified]
Statistical Test of Hypothesis P-Value 0.1815
Comments P-value ≥ 0.05; therefore, all secondary outcome measures listed after this outcome measure in the hierarchy were not tested.
Method Cochran-Mantel-Haenszel
Comments [Not Specified]
Method of Estimation Estimation Parameter Risk Difference (RD)
Estimated Value 5.2
Confidence Interval (2-Sided) 95%
-2.4 to 12.9
Estimation Comments [Not Specified]
7.Secondary Outcome
Title Percentage of Participants With Rescue Medication Use Within 24 Hours Post-dose
Hide Description Participants who did not experience relief of their migraine headache at the end of 2 hours after dosing with study medication (and after the 2-hour assessments had been completed on the eDiary) were permitted to use the following rescue medications: aspirin, ibuprofen, acetaminophen up to 1000 mg/day (this includes Excedrin Migraine), naproxen (or any other type of nonsteroidal anti-inflammatory drug), antiemetics (e.g., metoclopramide or promethazine), or baclofen. The participant's use of rescue medication was recorded by the participant in a paper diary.
Time Frame 24 hours post-dose
Hide Outcome Measure Data
Hide Analysis Population Description
The analysis was performed on mITT participants.
Arm/Group Title Rimegepant 75 mg Placebo
Hide Arm/Group Description:
Participants were administered a single oral dose of 75 mg of rimegepant on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Participants were administered a single oral dose of matching placebo for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Overall Number of Participants Analyzed 543 541
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants
20.4
(17.1 to 23.8)
31.8
(27.9 to 35.6)
8.Secondary Outcome
Title Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-dose
Hide Description Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eDiary. Sustained pain freedom was defined as pain level of none at 2 hours up to 24 hours post-dose with no rescue medication use through 24 hours post-dose.
Time Frame From 2 hours up to 24 hours post-dose
Hide Outcome Measure Data
Hide Analysis Population Description
The analysis was performed on mITT participants.
Arm/Group Title Rimegepant 75 mg Placebo
Hide Arm/Group Description:
Participants were administered a single oral dose of 75 mg of rimegepant on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Participants were administered a single oral dose of matching placebo for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Overall Number of Participants Analyzed 543 541
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants
14.0
(11.1 to 16.9)
8.1
(5.8 to 10.4)
9.Secondary Outcome
Title Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-dose
Hide Description Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eDiary. Sustained pain relief was defined as pain level of none or mild at 2 hours up to 24 hours post-dose with no rescue medication use through 24 hours post-dose.
Time Frame From 2 hours up to 24 hours post-dose
Hide Outcome Measure Data
Hide Analysis Population Description
The analysis was performed on mITT participants.
Arm/Group Title Rimegepant 75 mg Placebo
Hide Arm/Group Description:
Participants were administered a single oral dose of 75 mg of rimegepant on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Participants were administered a single oral dose of matching placebo for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Overall Number of Participants Analyzed 543 541
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants
38.9
(34.8 to 43.0)
27.9
(24.2 to 31.7)
10.Secondary Outcome
Title Percentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-dose
Hide Description Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eDiary. Sustained pain freedom was defined as pain level of none at 2 hours up to 48 hours post-dose with no rescue medication use through 48 hours post-dose.
Time Frame From 2 hours up to 48 hours post-dose
Hide Outcome Measure Data
Hide Analysis Population Description
The analysis was performed on mITT participants.
Arm/Group Title Rimegepant 75 mg Placebo
Hide Arm/Group Description:
Participants were administered a single oral dose of 75 mg of rimegepant on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Participants were administered a single oral dose of matching placebo for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Overall Number of Participants Analyzed 543 541
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants
11.6
(8.9 to 14.3)
7.2
(5.0 to 9.4)
11.Secondary Outcome
Title Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-dose
Hide Description Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eDiary. Sustained pain relief was defined as pain level of none or mild at 2 hours up to 48 hours post-dose with no rescue medication use through 48 hours post-dose.
Time Frame From 2 hours up to 48 hours post-dose
Hide Outcome Measure Data
Hide Analysis Population Description
The analysis was performed on mITT participants.
Arm/Group Title Rimegepant 75 mg Placebo
Hide Arm/Group Description:
Participants were administered a single oral dose of 75 mg of rimegepant on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Participants were administered a single oral dose of matching placebo for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Overall Number of Participants Analyzed 543 541
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants
33.7
(29.7 to 37.7)
23.9
(20.3 to 27.4)
12.Secondary Outcome
Title Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose
Hide Description Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eDiary. Pain relapse was defined as pain level of mild, moderate, or severe after 2 hours up to 48 hours for the participants who were pain-free at 2 hours post-dose.
Time Frame From 2 hours up to 48 hours post-dose
Hide Outcome Measure Data
Hide Analysis Population Description
The analysis population was performed on mITT participants with pain freedom at 2 hours post-dose.
Arm/Group Title Rimegepant 75 mg Placebo
Hide Arm/Group Description:
Participants were administered a single oral dose of 75 mg of rimegepant on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Participants were administered a single oral dose of matching placebo for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Overall Number of Participants Analyzed 104 77
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants
40.1
(30.6 to 49.6)
50.0
(39.0 to 61.0)
13.Secondary Outcome
Title Percentage of Participants With Freedom From Functional Disability at 2 Hours Post-dose
Hide Description Functional disability level was assessed in the eDiary on a 4-point scale: normal function, mild impairment, severe impairment, required bed rest. Freedom from functional disability was defined as normal function.
Time Frame 2 hours post-dose
Hide Outcome Measure Data
Hide Analysis Population Description
The analysis was performed on mITT participants.
Arm/Group Title Rimegepant 75 mg Placebo
Hide Arm/Group Description:
Participants were administered a single oral dose of 75 mg of rimegepant on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Participants were administered a single oral dose of matching placebo for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Overall Number of Participants Analyzed 543 541
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants
33.3
(29.4 to 37.3)
21.8
(18.4 to 25.3)
Time Frame Serious adverse events (SAEs) were collected from informed consent up to the end of study, and adverse events (AEs) were collected from randomization up to the end of the study (up to 52 days).
Adverse Event Reporting Description The safety population, all enrolled participants who received at least 1 dose of rimegepant or placebo, was used to determine the number of participants at risk for SAEs and other AEs.
 
Arm/Group Title Rimegepant 75 mg Placebo
Hide Arm/Group Description Participants were administered a single oral dose of 75 mg of rimegepant on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization. Participants were administered a single oral dose of matching placebo for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
All-Cause Mortality
Rimegepant 75 mg Placebo
Affected / at Risk (%) Affected / at Risk (%)
Total   0/546 (0.00%)      0/549 (0.00%)    
Hide Serious Adverse Events
Rimegepant 75 mg Placebo
Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total   2/546 (0.37%)      1/549 (0.18%)    
Gastrointestinal disorders     
Colitis  1  0/546 (0.00%)  0 1/549 (0.18%)  1
Respiratory, thoracic and mediastinal disorders     
Acute Respiratory Failure  1  1/546 (0.18%)  1 0/549 (0.00%)  0
Pulmonary Embolism  1  1/546 (0.18%)  1 0/549 (0.00%)  0
1
Term from vocabulary, MedDRA 20.0
Indicates events were collected by systematic assessment
Hide Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events 5%
Rimegepant 75 mg Placebo
Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total   0/546 (0.00%)      0/549 (0.00%)    
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
Layout table for Results Point of Contact information
Name/Title: Chief Medical Officer
Organization: Biohaven Pharmaceuticals, Inc.
Phone: 203-404-0410
EMail: clinicaltrials@biohavenpharma.com
Layout table for additonal information
Responsible Party: Biohaven Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03235479    
Other Study ID Numbers: BHV-3000-301
First Submitted: July 14, 2017
First Posted: August 1, 2017
Results First Submitted: November 30, 2020
Results First Posted: December 23, 2020
Last Update Posted: January 22, 2021